Frigo G M, Perucca E, Teggia-Droghi M, Gatti G, Visintini D, Calzetti S, Poloni M
Riv Patol Nerv Ment. 1976 Sep-Oct;97(5):305-14.
Plasma levels of diphenylhydantoin have been measured in 130 epileptic patients undergoing long-term anticonvulsant therapy. Only in a small percentage of the patients (15,38%) plasma levels were found to lie within the therapeutic range. Most patients (75,38%) exhibited subtherapeutic values, while in a few cases (9,24%) the upper limit of therapeutic range was exceeded. Although plasma concentrations significantly correlate with the administered dose, predictability of plasma levels in the individual patients given fixed dosage schedules is strongly limited by large interindividual variability. Sex, age and simultaneous administration of other drugs seem not to affect significantly DPH plasma levels. Our observations carried out in a meaningful sample of epileptic patients suggest that at present the practice of monitoring diphenylhydantoin plasma levels is still an essential tool for the management of epilepsy when a safe and effective therapeutic regimen is required.
对130名接受长期抗惊厥治疗的癫痫患者的血浆苯妥英水平进行了测定。只有一小部分患者（15.38%）的血浆水平处于治疗范围内。大多数患者（75.38%）的血浆水平低于治疗范围，而少数患者（9.24%）超过了治疗范围的上限。尽管血浆浓度与给药剂量显著相关，但在给予固定剂量方案的个体患者中，由于个体间差异较大，血浆水平的可预测性受到很大限制。性别、年龄和同时使用其他药物似乎对苯妥英的血浆水平没有显著影响。我们在一个有意义的癫痫患者样本中进行的观察表明，目前，当需要安全有效的治疗方案时，监测苯妥英血浆水平的做法仍然是癫痫管理的一项重要工具。
